IL2 and hereditary clear cell renal cell carcinoma: This indicates that IL-2 and IFN-α have anti-tumor activity in renal cell carcinoma, and the triple immunotherapy that adds 5-fluorouracil to enhance the clinical therapeutic effect (147).